A detailed history of First Horizon Advisors, Inc. transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, First Horizon Advisors, Inc. holds 109 shares of VKTX stock, worth $7,179. This represents 0.0% of its overall portfolio holdings.

Number of Shares
109
Previous 84 29.76%
Holding current value
$7,179
Previous $6,000 16.67%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 19, 2024

BUY
$47.39 - $80.2 $1,184 - $2,005
25 Added 29.76%
109 $5,000
Q1 2024

Apr 26, 2024

BUY
$17.4 - $94.5 $1,461 - $7,938
84 New
84 $6,000
Q4 2021

Feb 09, 2022

SELL
$4.6 - $6.72 $3,730 - $5,449
-811 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$5.58 - $7.04 $1,400 - $1,767
251 Added 44.82%
811 $5,000
Q3 2021

Nov 09, 2021

SELL
$5.58 - $7.04 $1,400 - $1,767
-251 Reduced 30.95%
560 $3,000
Q4 2018

Feb 11, 2019

BUY
$7.16 - $16.21 $5,806 - $13,146
811 New
811 $6,000

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $5.05B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track First Horizon Advisors, Inc. Portfolio

Follow First Horizon Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Horizon Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on First Horizon Advisors, Inc. with notifications on news.